Political contribution deductions require genuine transactions; banking records and party registration alone cannot defeat evidence of accommodation e...
Post-death GST liability permits fresh proceedings against legal representatives, while discontinued-business recovery remains limited to the inherite...
Non-confirmation of FEMA seizure prevents adjudicators from overriding pending appellate findings on recorded reasons and suspected foreign asset hold...
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
